Fort Point Capital Partners LLC Sells 8,153 Shares of Gilead Sciences, Inc. $GILD

Fort Point Capital Partners LLC trimmed its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 71.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,210 shares of the biopharmaceutical company’s stock after selling 8,153 shares during the period. Fort Point Capital Partners LLC’s holdings in Gilead Sciences were worth $356,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in GILD. Corundum Trust Company INC bought a new position in shares of Gilead Sciences during the third quarter valued at approximately $26,000. Howard Hughes Medical Institute bought a new stake in shares of Gilead Sciences during the 2nd quarter worth approximately $30,000. MTM Investment Management LLC boosted its holdings in Gilead Sciences by 176.0% during the 3rd quarter. MTM Investment Management LLC now owns 276 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 176 shares during the period. Kilter Group LLC purchased a new position in Gilead Sciences during the 2nd quarter valued at $33,000. Finally, Millstone Evans Group LLC grew its position in Gilead Sciences by 58.7% in the 3rd quarter. Millstone Evans Group LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $35,000 after acquiring an additional 118 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Stock Performance

GILD stock opened at $145.21 on Tuesday. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. The business has a 50-day moving average price of $141.16 and a 200 day moving average price of $127.19. The company has a market capitalization of $180.27 billion, a P/E ratio of 21.45, a PEG ratio of 1.90 and a beta of 0.36. Gilead Sciences, Inc. has a 1-year low of $93.37 and a 1-year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.83 by $0.03. The company had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The firm’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the prior year, the business earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Friday, March 13th. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio is currently 48.45%.

Analysts Set New Price Targets

A number of analysts have weighed in on the company. Sanford C. Bernstein reiterated an “outperform” rating and issued a $160.00 target price on shares of Gilead Sciences in a research note on Wednesday, February 11th. Truist Financial upped their price target on shares of Gilead Sciences from $145.00 to $152.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Citigroup reaffirmed a “buy” rating on shares of Gilead Sciences in a research note on Friday, March 6th. Cantor Fitzgerald lifted their price objective on shares of Gilead Sciences from $135.00 to $155.00 and gave the company an “overweight” rating in a report on Wednesday, February 11th. Finally, Argus upped their target price on shares of Gilead Sciences from $135.00 to $165.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. Twenty-four analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $157.62.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the company’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total transaction of $617,500.00. Following the completion of the sale, the director owned 8,920 shares in the company, valued at $1,101,620. This represents a 35.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $154.44, for a total value of $4,324,320.00. Following the sale, the insider directly owned 120,288 shares in the company, valued at $18,577,278.72. This trade represents a 18.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 303,280 shares of company stock valued at $43,203,470 in the last ninety days. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.